Lista de obras - Adam V. Patterson - Dominio Público Uruguay

2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L⁸⁵⁸R/T⁷⁹⁰M).

artículo científico publicado en 2015

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.

artículo científico publicado en 2004

2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors

artículo científico publicado en 2017

2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors

artículo científico publicado en 2017

3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.

artículo científico publicado en 2003

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells

artículo científico publicado en 2014

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.

artículo científico publicado en 2009

Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers

scholarly article

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress

artículo científico publicado en 2016

Alanine scan-guided synthesis and biological evaluation of analogues of culicinin D, a potent anticancer peptaibol

artículo científico publicado en 2020

Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours.

artículo científico publicado en 2002

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

artículo científico publicado en 2015

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia

artículo científico

Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.

artículo científico publicado en 2007

Bystander or no bystander for gene directed enzyme prodrug therapy

artículo científico publicado en 2009

Can gene therapy overcome the problem of hypoxia in radiotherapy?

artículo científico publicado en 2000

Cancer chemotherapy and drug metabolism.

artículo científico publicado en 2005

Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro

artículo científico publicado en 2012

Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000.

artículo científico publicado en 2014

Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

artículo científico publicado en 2010

Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.

artículo científico publicado en 2013

Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation.

artículo científico publicado en 2004

DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.

artículo científico publicado en 2009

DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine

artículo científico publicado en 2004

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents

artículo científico publicado en 2021

Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia

artículo científico publicado en 2011

Directed evolution of the B. subtilis nitroreductase YfkO improves activation of the PET-capable probe SN33623 and CB1954 prodrug

artículo científico publicado en 2020

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.

artículo científico publicado en 2009

Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer

artículo científico publicado en 2018

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

artículo científico publicado en 1999

Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells.

artículo científico publicado en 2005

E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications

scientific article published on 21 August 2020

Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug Therapy

artículo científico publicado en 2019

Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.

artículo científico publicado en 2017

Enzymology of tirapazamine metabolism: a review

artículo científico publicado en 1998

Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy

artículo científico publicado en 2018

Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy, Advances and Prospects

artículo científico publicado en 2018

Harmine Induces Adipocyte Thermogenesis through RAC1-MEK-ERK-CHD4 Axis

artículo científico publicado en 2016

Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines ⬇️

artículo científico publicado el 15 de octubre de 2003

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

artículo científico publicado en 2019

Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia

artículo científico publicado en 2007

Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5

artículo científico publicado en 2014

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

artículo científico publicado en 1995

Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase

artículo científico publicado en 1995

Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications

artículo científico publicado en 2022

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

artículo científico publicado en 2007

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.

artículo científico publicado en 2011

N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors

artículo científico publicado en 2015

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line

artículo científico publicado en 2000

Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators

artículo científico publicado en 2009

Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility

artículo científico

Novel chimeric gene promoters responsive to hypoxia and ionizing radiation.

artículo científico publicado en 2002

Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.

artículo científico publicado en 2008

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069 ⬇️

artículo científico publicado el 1 de enero de 1997

Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine

artículo científico publicado en 2007

Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours

artículo científico publicado en 2002

Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs

artículo científico publicado en 2004

Pre-Clinical Activity of Novel Hypoxia-Activated FLT3 Inhibitors in FLT3-Mutated AML ⬇️

artículo científico publicado en 2016

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.

artículo científico publicado en 2015

Prodrugs in genetic chemoradiotherapy.

artículo científico publicado en 2003

Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study

artículo científico publicado en 2019

Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy

artículo científico publicado en 2013

Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator

scientific article published on 14 March 2006

Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy

artículo científico publicado en 2016

Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.

artículo científico publicado en 2010

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3

artículo científico publicado en 2021

Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.

artículo científico publicado en 2009

Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4

scientific article published on 03 July 2019

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506

artículo científico publicado en 2021

Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells.

artículo científico publicado en 2012

Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase

artículo científico publicado en 2009

Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623

artículo científico publicado en 2024

Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine

artículo científico publicado en 2003

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity

artículo científico publicado en 2020

Synthesis and antiproliferative activity of C- and N-terminal analogues of culicinin D

artículo científico publicado en 2020

Synthesis and antiproliferative activity of culicinin D analogues containing simplified AHMOD-based residues

artículo científico publicado en 2019

Synthesis and cytotoxicity of pyranonaphthoquinone natural product analogues under bioreductive conditions.

artículo científico publicado en 2013

Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy

artículo científico publicado en 2007

TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure

artículo científico publicado en 2019

Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954.

artículo científico publicado en 2012

Targeting gene expression to hypoxic tumor cells

article

Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes

artículo científico publicado en 2020

The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition

artículo científico publicado en 2015

The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy

artículo científico publicado en 2013

The bioreductive agent RH1 and gamma-irradiation both cause G2/M cell cycle phase arrest and polyploidy in a p53-mutated human breast cancer cell line

artículo científico publicado en 2004

The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3

artículo científico publicado en 2010

The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.

artículo científico publicado en 2004

The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).

artículo científico publicado en 2007

The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions

artículo científico publicado en 2000

The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).

artículo científico publicado en 1994

Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro

artículo científico publicado en 1998

Toward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs.

artículo científico publicado en 2014

Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy

artículo científico publicado en 2021

Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours

artículo científico publicado en 2021

Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts

artículo científico publicado en 2003

Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence

artículo científico publicado en 2013

uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954.

artículo científico publicado en 2010

Lista de obras de Adam V. Patterson

2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L⁸⁵⁸R/T⁷⁹⁰M).

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.

2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors

2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors

3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.

Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress

Alanine scan-guided synthesis and biological evaluation of analogues of culicinin D, a potent anticancer peptaibol

Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours.

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia

Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.

Bystander or no bystander for gene directed enzyme prodrug therapy

Can gene therapy overcome the problem of hypoxia in radiotherapy?

Cancer chemotherapy and drug metabolism.

Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro

Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000.

Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.

Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation.

DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.

DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents

Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia

Directed evolution of the B. subtilis nitroreductase YfkO improves activation of the PET-capable probe SN33623 and CB1954 prodrug

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.

Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells.

E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications

Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug Therapy

Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.

Enzymology of tirapazamine metabolism: a review

Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy

Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy, Advances and Prospects

Harmine Induces Adipocyte Thermogenesis through RAC1-MEK-ERK-CHD4 Axis

Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines ⬇️

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia

Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase

Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.

N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line

Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators

Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility

Novel chimeric gene promoters responsive to hypoxia and ionizing radiation.

Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069 ⬇️

Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine

Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours

Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs

Pre-Clinical Activity of Novel Hypoxia-Activated FLT3 Inhibitors in FLT3-Mutated AML ⬇️

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.

Prodrugs in genetic chemoradiotherapy.

Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study

Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy

Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator

Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy

Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3

Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.

Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506

Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells.

Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase

Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623

Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity

Synthesis and antiproliferative activity of C- and N-terminal analogues of culicinin D

Synthesis and antiproliferative activity of culicinin D analogues containing simplified AHMOD-based residues

Synthesis and cytotoxicity of pyranonaphthoquinone natural product analogues under bioreductive conditions.

Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy

TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure